ZIOPHARM Oncology Shares Charge Higher After Phase 3 Trial of Palifosfamid Reaches Target Number of Progression-Free Survival Events
February 12, 2013 at 10:31 AM EST
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP ) shares are up more than 14 percent Tuesday morning following results from the Phase 3 (PICASSO 3) trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma which reached its target number of progression-free survival (PFS) events. PICASSO 3 is an international, randomized, double-blind, placebo-controlled trial
